0
0
1/7/26 at 7:10am
Organization
Gsk.com
39 words
0
Comments
Bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate
You are the first to view
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-b-well-1-and-b-well-2-phase-iii-trials-for-bepirovirsen-a-potential-first-in-class-treatment-for-chronic-hepatitis-b/
Create an account
or login to join the discussion